Ignite Creation Date:
2025-12-25 @ 3:27 AM
Ignite Modification Date:
2025-12-26 @ 2:08 AM
Study NCT ID:
NCT04865705
Status:
UNKNOWN
Last Update Posted:
2021-04-29
First Post:
2020-10-26
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer
Sponsor:
West China Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-11-10
Start Date Type:
ACTUAL
Primary Completion Date:
2021-12-10
Primary Completion Date Type:
ESTIMATED
Completion Date:
2022-06-10
Completion Date Type:
ESTIMATED
First Submit Date:
2020-10-26
First Submit QC Date:
None
Study First Post Date:
2021-04-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-04-28
Last Update Post Date:
2021-04-29
Last Update Post Date Type:
ACTUAL